Introduction {#S1}
============

Human T-lymphotropic virus (HTLV) was the first RNA retrovirus to be associated with cancer ([@B20]). To date, four HTLV related viruses (types 1 to 4) have been discovered, but only HTLV-1 and HTLV-2 have been convincingly linked to human diseases ([@B20]; [@B12]; [@B4]; [@B24]). HTLV-1 is the etiologic agent of Adult T-cell leukemia (ATL) and HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) ([@B22]). HTLV is mainly spread via mother-to-child transmission, sexual contact, and through contaminated needles shared by drug users. It also can be transmitted through the transfusion of infected blood components and tainted liver, kidney, or lung transplants. To mitigate these risks, mandatory screening of blood supplies for HTLV-1/2 was implemented in the mid-1980s in most developed and several developing countries ([@B23]; [@B14]). However, because most regions of China have long been considered non-endemic for HTLV, limited screening has been implemented.

Currently, initial diagnosis of HTLV-1/2 infection is mainly based on detecting specific antibodies in plasma or serum using enzyme-linked immunosorbent assay (ELISA) and CLIA or ECLIA. Several commercial kits based on recombinant and/or synthetic peptide antigens alone or in combination with viral lysates have also been adapted for large-scale screening of HTLV-1/2 antibodies. However, the kits fail to differentiate between HTLV-1 and HTLV-2 infections because the two types share a high homology between them ([@B2]; [@B8]). Besides, the high false-positive rate of these commercial assays, especially in low-seroprevalence populations, is a major problem. Therefore, confirmatory assays with high specificity are required for samples exhibiting a signal repeatedly greater than or equal to the threshold value of the screening assays.

Western blot is most frequently used to confirm the presence of anti-HTLV-1/-2 antibodies. The FDA-licensed MP Diagnostics HTLV Blot 2.4 uses a combination of recombinant HTLV-1/2 proteins and HTLV-1 viral lysate to improve sensitivity. This assay also uses HTLV type-specific recombinant envelope protein (gp46-1 and gp46-2) to discriminate viral types ([@B21]). However, a large number of WB-indeterminate and WB-untypable results are commonly found in several population groups and especially among low-risk blood donors ([@B15]; [@B3]; [@B25]). To address this shortcoming, another serologic confirmatory test with improved sensitivity, INNO-LIA HTLV, has been developed to confirm and differentiate HTLV-1 and HTLV-2 infections ([@B26]). This assay appeared useful in reducing the numbers of inconclusive WB results ([@B26]).

Molecular assay is another method used for HTLV confirmation. Real-time PCR or quantitative PCR (qPCR) have been used to determine the real status of HTLV infections and quantify the proviral load (PVL). However, these molecular assays have had low sensitivity in special population groups, such as individuals infected with HIV or HTLV-2 ([@B19]; [@B5]).

Although several commercially available HTLV-1/2 diagnostic assays have been used worldwide, their performance in endemic and non-endemic areas varies greatly. Moreover, few studies have been conducted to compare the performance of LIA and WB in low-prevalence populations. Therefore, the objective of this study was to evaluate several FDA- or CE-licensed HTLV-1/2 assays to diagnose the specimens that were RR to one ELISA, and to discuss strategies for the diagnosis of HTLV-1/2 infection in a non-endemic area.

Materials and Methods {#S2}
=====================

Samples and Study Design {#S2.SS1}
------------------------

All specimens were collected from eligible donors from blood banks/centers in 26 provinces in China between January 2016 and April 2019. The RR samples were delivered at 2--8°C or frozen to the NCCL for confirmation. The RR samples were also HBsAg, anti-HCV, anti-HIV, and anti-TP negative by both two screening ELISAs in the enrolled blood centers. According to the confirmatory process ([Figure 1](#F1){ref-type="fig"}), all RR samples were simultaneously subjected to four screening assays in the NCCL. Samples reactive to any one of the four assays were further confirmed by a LIA (INNO-LIA HTLV I/II score, Fujirebio, Japan) and WB (MP HTLV Blot 2.4, MP Biomedicals, Singapore).

![The testing algorithms of HTLV-1/2 in our study. WB, western blot; ELISA, enzyme-linked immunosorbent assays; CLIA, chemiluminescence immunoassays; ECLIA, electrochemiluminescence immunoassays; RR, repeatedly reactive. +: positive/reactive; --: negative/non-reactive; +/--: indeterminate.](fmicb-11-01151-g001){#F1}

Samples with limited plasma volumes that were not enough for all assays were excluded from our study. Enrolled samples with a positive result either by WB or LIA were classified as positive. Positive or indeterminate specimens with whole blood available were further quantified by qPCR in our lab. In addition, blood donations with an indeterminate result were recollected from the same donor, and retested by the same detection process.

Screening and Evaluated Assays {#S2.SS2}
------------------------------

Three different kinds of commercially available ELISA assays \[Wantai HTLV-1/2 antibody ELISA kits (Wantai BioPharm, China), Murex HTLV I+II (Diasorin S.p.A., United Kingdom) and Foresight HTLV-1/2 antibody ELISA kits (Acon Biotech, China)\] were used for screening HTLV1/2 antibodies at all participating blood centers/banks in China. Reactive specimens were retested by the same assay and any one of two-round retests found to be reactive were defined as RR specimen.

Further detection was done in the NCCL using Elecsys HTLV-I/II (Roche Diagnostics, Germany), Lumipulse G HTLV-I/II (Fujirebio, Japan) and two kinds of ELISA assays (Murex HTLV I+II (Diasorin S.p.A., United Kingdom) and Avioq HTLV-I/II Microelisa System (Avioq, Durham, NC, United State). The key features of the evaluated assays are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Technical features of evaluated assays and confirmatory assays used in the study.

  Assay name                          Manufacturer        Assay type                                                      Detection antigens                                                           Testing time
  ----------------------------------- ------------------- --------------------------------------------------------------- ---------------------------------------------------------------------------- --------------
  Elecsys HTLV-I/II                   Roche diagnostics   One-step double-antigen sandwich chemiluminescent immunoassay   Viral recombinant antigens gp21 and p24                                      18 min
  Lumipulse G HTLV-I/II               Fujirebio           Two-step sandwich chemiluminescent immunoassay                  Recombinant antigens p19 I/II, p24 I/II, gp46 I/II, gp21 I                   4 min
  Avioq HTLV-I/II Microelisa System   Avioq               ELISA                                                           Viral antigens (purified viral lysate) and recombinant HTLV-1 p21E antigen   150 min
  Murex HTLV-I/II                     Diasorin            ELISA                                                           HTLV-1 and HTLV-2 antigens                                                   90 min
  INNO-LIA HTLV I/II score            Fujirebio           A line immunoassay                                              Recombinant antigens p19 I/II, p24 I/II, gp46 I/II, gp21 I/II                18 h
  MP HTLV Blot 2.4                    MP Biomedicals      Western Blot assay                                              Recombinant HTLV-1/2 antigens and HTLV-1 viral lysate                        150 min

ELISA, enzyme-linked immunosorbent assay.

Confirmatory Tests {#S2.SS3}
------------------

In the LIA, the strips contained recombinant proteins (rp19 I/II, rp24 I/II, and rgp21 I/II) for confirmation and synthetic peptides (gp46 I, p19 I, and gp46 II) for differentiation of HTLV-1 and HTLV-2 antibodies. Samples were considered HTLV positive if they were reactive with at least two confirmation bands, including rgp21 I/II. The positive samples were typed as HTLV-1 if the intensities of gp46 I and p19 I bands were equivalent to or higher than that of the gp46 II band. HTLV-2 positivity was defined if the gp46 II band were more intense than the gp46 I and p19 I bands and if no discriminate bands appeared, an untypable HTLV result was denoted. A specimen was classified as indeterminate if it were reactive with one band (rgp21 I/II) or two bands (except rgp21 I/II). Samples were considered negative if a single rp24 I/II, rp19 I/II, gp46 I, or gp46 II band or no bands appeared.

WB is most frequently used as a supplemental assay for confirming and differentiating the presence of antibodies against HTLV. Results of MP HTLV Blot 2.4 were interpreted according to the stringent criteria provided by the manufacturer. Briefly, HTLV-1 seropositivity was defined as reactivity to gag (p19 with or without p24) and two env (GD21 and rgp46-I). HTLV-2 seropositivity was defined as reactivity to gag (p24 with or without p19) and two env (GD21 and rgp46-II). Samples that were reactive to both gag (p19 and p24) and env (GD21) were defined as HTLV seropositive but were considered untypable. Any other patterns of specific bands that did not meet the above criteria were considered as indeterminate. Absence of bands or appearance of non-specific band patterns were interpreted as negative.

Quantitative PCR (qPCR) {#S2.SS4}
-----------------------

DNA was extracted from whole blood of each specimen using the Tiangen Magnetic Blood Genomic DNA Kit (Tiangen Biotech, China). HTLV-1 proviral DNA was detected and quantified by qPCR using a set of primer pairs and a TaqMan probe targeting the HTLV-1 pol region. The RPPH1 gene was also amplified simultaneously as an internal control. The primers and probes are shown in [Supplementary Table S1](#DS1){ref-type="supplementary-material"}. Standard curves were generated using recombinant plasmid DNA with HTLV-1 pol and RPPH1 sequences. Normalized HTLV-1 PVL was calculated using the formula: (HTLV-1 DNA average copy number/RPPH1 average copy number) × 2 × 100 leukocytes and expressed as the number of HTLV-1 copies per 100 PBMCs. The detection limit for the HTLV-1 pol region was estimated to be 2.5 copies per 10,000 host leukocytes with a 95% hit-rate.

Statistical Analysis {#S2.SS5}
--------------------

The PPVs were calculated by SPSS version 21.0 (IBM, Corp., Armonk, NY, United States). Descriptive statistics are presented as geometric means + standard deviations. Results were analyzed with *t*-test. *p* \< 0.05 was considered statistically significant.

Results {#S3}
=======

HTLV Confirmation and Typing {#S3.SS1}
----------------------------

A total of 1546 RR samples with enough volumes were included in the final sample count in our study. Of the 1546 samples, 555 showed discordant results and 991 showed consistent results across the four assays. Of the 991 consistent samples, 44 were reactive to all four assays while the rest were negative in all assays. Finally, 599 samples that were reactive to at least one assay were confirmed by LIA and WB. Of these samples, 73.29% (439/599) showed consistent results in the two confirmatory tests, including 44 HTLV-1 positive samples, 8 indeterminate samples and 387 negative samples ([Table 2](#T2){ref-type="table"}). As samples were defined as positive if any confirmatory test were positive, 48 samples were finally identified as HTLV-1 positive, 13 as HTLV positive, 151 as indeterminate and 387 as negative. In addition, 41 blood samples were also tested by qPCR, which showed that 6 HTLV-1 positive samples and 1 HTLV-untyped samples were NAT-positive and 30 indeterminate samples were NAT-negative. The results and validation algorithm are shown in [Figure 1](#F1){ref-type="fig"}.

###### 

INNO-LIA results compared to WB results.

  WB results   LIA results   Total               
  ------------ ------------- ------- ----- ----- -----
  HTLV-1       44            1       0     0     45
  Ind          2             4       8     13    27
  Neg          1             9       130   387   527
  Total        47            14      138   400   599

LIA, line immunoassay; WB, western blot; Ind, indeterminate, Neg, negative.

As shown in the [Table 2](#T2){ref-type="table"}, 61 samples were interpreted as positive using the LIA as a reference. The positive detection rates for the four screening assays ranged from 72.1 to 91.8% ([Table 3](#T3){ref-type="table"} and [Supplementary Table S2](#DS1){ref-type="supplementary-material"}). A combination of any two of the four assays increased the positive detection rate. We found that the combination of Roche-ECLIA and Murex-ELISA detected 98.4% positives, which was higher than other combinations. However, only 44 samples were classified as positive when WB was used as a standard and the positive detection rates were increased to 93.2, 97.2, 100, and 100% for Avioq-ELISA, Murex-ELISA, Roche-ECLIA, and Fujirebio-CLIA, respectively ([Supplementary Table S2](#DS1){ref-type="supplementary-material"}).

###### 

Details of the discrepant results by LIA and WB among the finally confirmed HTLV positive samples.

  Sample no.   ELISA   CLIA    LIA     WB 2.4   qPCR                                                                                                                             
  ------------ ------- ------- ------- -------- -------------------------------------------------- -------- -------------------------------------------------- -------- -------- --------
  1626         1.787   3.315   427.9   50.0     p19 I/II, p24 I/II, gp46 I/II, gp21 I/II, gp46-I   HTLV-1   p19, p24, p26, p28, p32, p36, p53, pg46            Ind      0.339    HTLV-1
  1705         1.166   3.297   77.8    50.0     p19 I/II, gp46 I/II, gp21 I/II, gp46-I             HTLV-1   p19, rgp46-I                                       Ind      11.397   HTLV-1
  359          5.323   9.409   343.9   50.0     p19 I/II, p24 I/II, gp46 I/II, gp21 I/II           HTLV     p19, p24, p26, p28, p32, p36, p53, GD21, rgp46-I   HTLV-1   /        NT
  1739         1.146   3.49    178.2   50.0     p19 I/II,gp21 I/II, gp46-I                         HTLV     p19, p26, p28, GD21                                Ind      0.009    HTLV-1
  525          0.14    0.43    1.12    3.1      gp46 I/II, gp21 I/II, gp46-I                       HTLV-1   /                                                  Neg      /        NT
  495          0.19    0.40    1.9     8.4      p19 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        NT
  1441         0.34    0.55    11.95   5.6      p19 I/II, gp21 I/II                                HTLV     p19                                                Ind      /        Neg
  1747         0.074   2.02    42.31   0.6      p19 I/II, gp21 I/II                                HTLV     rgp46-II                                           Ind      /        Neg
  53           0.142   2.212   0.215   1.8      p24 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        NT
  1412         0.17    2.59    0.472   1.3      p19 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        NT
  816          0.24    1.86    0.136   0.3      p19 I/II, gp21 I/II                                HTLV     p19, p26                                           Ind      /        NT
  1295         0.15    1.02    0.4     0.9      p19 I/II, p24 I/II, gp21 I/II                      HTLV     /                                                  Neg      /        Neg
  489          0.16    0.35    5.18    0.1      p19 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        NT
  647          0.13    0.45    4.15    0.9      p19 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        NT
  1285         0.29    0.36    1.32    0.7      p24 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        NT
  1461         0.32    0.38    1.47    0.4      p24 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        Neg
  457          0.190   0.780   0.727   3.1      p19 I/II, gp21 I/II                                HTLV     /                                                  Neg      /        NT

Correlation Between the PPVs and the Reactivity Index of the Evaluated Commercial Assays {#S3.SS2}
----------------------------------------------------------------------------------------

In each assay, positive samples confirmed by LIA and WB displayed a significantly higher reactivity index than indeterminate (*p* \< 0.0001) and negative samples (*p* \< 0.0001) ([Figure 2](#F2){ref-type="fig"}). Moreover, the difference in reactivity indexes between indeterminate and negative samples as detected by the evaluated assays was also statistically significant (*p* \< 0.05), indicating that reactivity indexes may correlate with the confirmatory results.

![S/CO or COI values distribution among the finally confirmed positive, indeterminate and negative samples. Ind, indeterminate, Pos, positive; Neg, negative.](fmicb-11-01151-g002){#F2}

To determine the relationship between PPVs and reactivity indexes on four evaluated assays, we analyzed the results of the assays at different cut-off reactivity indexes for the four assays ([Table 4](#T4){ref-type="table"}). We found that when the cut-off values were 1.0, the PPV for Avioq-ELISA was 91.7%, but for Murex-ELISA, Roche-ECLIA and Fujirebio-CLIA the PPVs were only 29.5, 21.0, and 23.7%, respectively. PPVs above 95% were observed when cut-off values were 1.5 for Avioq-ELISA, 10.0 for Murex-ELISA, 29.0 for Roche-ECLIA and 8.8 for Fujirebio-CLIA. PPVs were 100% when the cut-off ratios for Avioq-ELISA, Murex-ELISA, Roche-ECLIA and Fujirebio-CLIA were 2.5, 11.0, 67.2, and 28.0, respectively.

###### 

Relationship between S/CO or COI values and PPV.

  Avioq-ELISA    Murex-ELISA   Roche-ECLIA   Fujirebio-CLIA                                      
  -------------- ------------- ------------- ---------------- ---------- ------------ ---------- ------------
  1.00           91.7%         1.0           29.5%            1.0        21.0%        1.0        23.7%
  1.05           93.6%         4.0           79.6%            20.0       90.6%        8.0        89.1%
  **1**.**50**   **95.5%**     8.0           88.1%            28.0       94.1%        8.4        92.5%
  1.80           97.5%         9.8           92.9%            **29.0**   **96.0%**    **8.8**    **96.0%**
  2.00           97.4%         **10.0**      **96.0%**        40.0       98.0%        12.0       98.0%
  **2**.**50**   **100.0%**    **11.0**      **100.0%**       **67.2**   **100.0%**   **28.0**   **100.0%**

LIA, line immunoassay; PPV, positive predictive value. The cut-off values were showed in bold when the PPVs reached to 95% or 100%.

Discrepancies Between INNO-LIA and WB in the Finally Confirmed Positive Samples {#S3.SS3}
-------------------------------------------------------------------------------

Seventeen samples that were finally defined as HTLV-1 or HTLV positive showed discrepant results between INNO-LIA and WB ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Of these 17 samples, 3 were LIA HTLV-1 positive and 14 were LIA HTLV positive but untypable. Two out of the 3 LIA HTLV-1 positives were also NAT-positive but were WB-indeterminate while the other one was WB-negative. One out of the 14 LIA-untyped samples was discriminated as HTLV-1 by WB, 4 were confirmed as WB-indeterminate and 9 were WB-negative. It is noteworthy that 1 LIA-untypable but WB-indeterminate sample was also NAT-positive.

After combining the results confirmed by LIA, WB and qPCR, 5 samples were classified as HTLV-1 positive and 12 samples were HTLV positive but untypable ([Table 3](#T3){ref-type="table"}). The average S/CO or COI values of the untyped HTLV infections for Murex-ELISA, Roche-ECLIA and Fujirebio-CLIA were 1.03, 5.49, and 2.09, respectively. All these untyped samples did not respond to Avioq-ELISA and their positive rates for Roche-ECLIA, Murex-ELISA and Fujirebio-CLIA were 7/12, 5/12 and 5/12, respectively, indicating that these specimens may easily be missed by some screening assays.

Characterization of Indeterminate Results {#S3.SS4}
-----------------------------------------

Of the 151 samples which were finally interpreted as indeterminate, 130 were LIA ± / WB-, 15 were LIA-/WB ± and 6 were indeterminate by both tests ([Tables 2](#T2){ref-type="table"}, [5](#T5){ref-type="table"}). Most of the LIA-indeterminate samples showed a gp21 I/II pattern while only a few displayed a p19 I/II plus p24 I/II pattern. Thirty LIA-indeterminate samples were available for qPCR detection, but none were positive. In the WB-indeterminate samples, a single rgp46-II band was the most frequently observed pattern, followed by a single GD21 and a single p19 band. Of these indeterminate samples, 68.7% were Roche-ECLIA positive, 54.3% were Fujirebio-CLIA positive, 43.7% were Murex-ELISA positive and only 0.4% were Avioq-ELISA positive.

###### 

The reactivity patterns of the indeterminate samples.

  Ind. pattern    INNO-LIA             WB reactivity   No.   qPCR results   No. of samples positive by the following assay/                                       
  --------------- -------------------- --------------- ----- -------------- ------------------------------------------------- ----------------- ----------------- -----------------
  INNO-LIA±/WB−   gp21 I/II            /               127   0/30           4/130 (0.3%)                                      54/130 (41.53%)   93/130 (71.5%)    72/130 (55.38%)
                  p19 I/II, p24 I/II   /               3     NT                                                                                                   
  INNO-LIA−/WB±   /                    rgp46-II        5     NT             2/15 (12.3%)                                      8/15 (53.3%)      9/15 (60.0%)      5/15 (33.3%)
                  /                    GD21            2                                                                                                          
                  /                    p19             3                                                                                                          
                  p19 I/II             p19             1                                                                                                          
                  p19 I/II             p24             1                                                                                                          
                  p19 I/II             p19, p26        1                                                                                                          
                  /                    rgp46-I         1                                                                                                          
                  p24 I/II             p24, rgp46-I    1                                                                                                          
  INNO-LIA±/WB±   gp21 I/II            GD21            3     NT             0/6 (0.00%)                                       4/6 (66.67%)      4/6 (66.67%)      5/6 (83.3%)
                  gp21 I/II            rgp46-I         1                                                                                                          
                  gp21 I/II            rgp46-II        1                                                                                                          
                  p19 I/II,p24 I/II    p19, p26        1                                                                                                          
  Total                                                151   0/30           6/151 (0.4%)                                      66/151 (43.7%)    103/151 (68.7%)   82/151 (54.3%)

LIA, line immunoassay; WB, western blot; ±, indeterminate; −, negative; NT, not tested.

Thirteen indeterminate samples were recollected from the same donors no less than 8 weeks after last donation and retested by all assays ([Supplementary Table S3](#DS1){ref-type="supplementary-material"}). Seroconversion occurred in 2 individuals with LIA ± /WB- results. Both samples converted from the single gp21 I/II band pattern to the gp21 I/II plus p19 I/II band pattern but were still WB-negative. In addition, 4 out of the 13 indeterminate samples, including 2 LIA ± /WB- samples and 2 LIA-/WB ± samples, converted to negative. Six recollected samples were also retested by qPCR, but all of them were NAT-negative, including the seroconverted LIA-HTLV positive sample.

Discussion {#S4}
==========

Currently, screening for HTLV-1/2 antibodies in healthy blood donors is not done routinely in China. A systematic review revealed that HTLV-1/2 prevalence in the coastal areas of China, and especially in Fujian province, is higher, compared to the low average HTLV-1/2 prevalence in the mainland ([@B6]). However, it is notable that in some provinces close to the high-endemic areas of China, including Hunan, Jiangsu and Guangxi, the prevalence is relatively high, probably due to large-scale population migration in these regions in recent years ([@B6]). Accordingly, HTLV-1/2 may have spread from the coastal areas to the mainland, resulting in increased opportunities for virus transmission and infection. Therefore, it is reasonable to expect HTLV-1/2 detection to become necessary in China. Consequently, appropriate strategies for screening and confirming HTLV-1/2 infection in China should be developed urgently.

In our study, almost one-third samples displayed discordant results among the four evaluated assays, which may due to the differences in the combination, source and quantity of HTLV-1/2 antigens used by different manufacturers. None of the evaluated assays could detect all the true HTLV positives when using LIA as a standard. In contrast, the Roche-ECLIA was a relatively more sensitive test that was reactive to 91.8% confirmed positive samples. This assay was especially sensitive to the untyped positives (7/12, 58.33%). Moreover, Roche-ECLIA could detect more indeterminate samples than the other three assays, indicating it was a sensitive method for screening HTLV-1/2 antibodies. From the perspective of blood banks/centers, sending RR samples to a reference lab is costly and time-consuming. Therefore, we propose that, where possible, such samples could be retested by the Roche-ECLIA and the positives subjected to subsequent confirmatory tests. Our data suggest that this would reduce the need for confirmation by about two thirds.

The present study indicated that most untypable HTLV infections had relatively low S/CO or COI values or were misdiagnosed by some screening tests, indicating a high risk of missed detections when only one screening assay is used in the reference labs. In our study, the combination of Roche-ECLIA and Murex-ELISA performed relatively well, detecting 98.4% true positives when LIA was the standard. We detected 100% positive samples when Murex-ELISA was combined with Roche-ECLIA and Fujirebio-CLIA but this strategy would be costly, time-consuming and labor intensive for reference labs.

HTLV-1-associated diseases develop in only a small proportion of infected individuals and slowly progress to disease relative to the average life span of humans. Consequently, after balancing screening/conformational costs and the threat of HTLV infections to public health especially in the non-endemic area, we recommend the use of a combination of Roche-ECLIA and Murex-ELISA in reference centers to retest initially reactive blood samples in low-risk areas. Since Roche-ECLIA is more sensitive than Murex-ELISA, it is best to test RR samples with Roche-ECLIA first and then the negatives by Murex-ELISA. Therefore, the number of test would be reduced by about 12% compared with test simultaneously.

Our results also indicate that higher S/CO or COI values were associated with higher diagnostic reliability. As demonstrated in this study, samples with S/CO values over 2.5, 11.0, 67.2 for Avioq-ELISA, Murex-ELISA, and Roche-ECLIA, respectively, or COI value over 28.0 for Fujirebio-CLIA, were rarely negative. Hence, samples with values above these thresholds can be interpreted as HTLV-1/2 positive, decreasing the demand and cost of confirmatory tests. Accordingly, if Murex-ELISA and Roche-ECLIA were combined for sample retesting in reference centers, the number of samples needing confirmation would reduce by 14.7%. Nevertheless, molecular assays or other supplementary tests would be necessary to determine PVL or HTLV infection types.

WB-indeterminate and/or untypable variants remain a serious problem worldwide. It has been found that the frequency of WB-indeterminate samples reactive to HTLV-1 ELSIA varies among different cohorts, but is much higher in low-risk blood donors ([@B17]; [@B1]). In our study, only 4.5% (27/599) of WB-indeterminate samples and no WB untypable samples were identified. The low sensitivity of WB and the special specimens collected from blood donors in the HTLV-1 infected area may account for these results. Of the WB-indeterminate samples, 22.2% (6/27) were confirmed positive by LIA and 11.1% (3/27) were further confirmed HTLV-1 positive by qPCR. Although most of the WB-indeterminate, LIA-positive samples (4/6) were LIA untypable, the results indicated that LIA was more sensitive than WB and, in our view, should be the first choice for confirmation.

Indeterminate WB patterns indicating true or false virus infection have been reported previously ([@B17]). In our study, rgp46-II alone was the most frequently observed pattern, which was remarkably different from the pattern observed in blood donors or general population from other regions ([@B10]; [@B18]; [@B13]; [@B9]), indicating that indeterminate WB patterns can vary among populations. [@B17] reported that the presence of p19 plus p24 seemed to indicate true reactivity and p24 alone indicated false reactivity. In our study, the p19 band was observed in 5/6 WB ± /LIA+ samples, 3 of which also exhibited another unique band (p24 or rgp46-I or GD21). Therefore, we suspected that the presence of p19 plus a unique GAG or ENV band indicated true HTLV infection and should be validated by LIA or molecular methods. In high-risk or endemic areas, indeterminate WB patterns may represent seroconverters ([@B11]; [@B17]). In this study, seroindeterminate blood donors were usually recalled for recollection. However, only three WB-indeterminate samples were returned, two of which showed faint rgp46-I or rgp46-II bands and were reassigned as negative. We estimated that a proportion of the WB-indeterminate samples were false reactions, but larger follow-up studies to test this notion should be performed.

Although LIA reduced the number of WB-indeterminate samples, the assay yielded more indeterminate (22.7%, 136/599) and untypable (2.3%, 14/599) results than WB. Most of the samples expressed a single gp21 I/II pattern (97.1%, 132/136), the largest of which had faint intensity (55.1%, 75/136). We propose several reasons for these inconclusive results, including low HTLV proviral loads, mutations in the provirus (defective particles), seroconversion period or cross-reactivity with other antigens or viruses. In our study, 30 LIA-indeterminate and 5 LIA-untyped samples were tested by qPCR, but only one LIA-untyped sample was confirmed HTLV-1 positive with a PVL of 0.009 copies/100 PMBC, indicating that samples with very low PVL may be hard to identify. [@B16] demonstrated that antibodies to rgp21 antigen appeared earlier than antibodies to p24 and p19, and the presence of the single rgp21 band may indicate an early HTLV infection. In our follow-up results, 2 out of 11 recollected samples with strong gp21 I/II intensity converted to HTLV-positive, suggesting a proportion of the LIA-indeterminate samples were in the seroconversion phase and needed to be followed-up. However, 2 samples with faint gp21 I/II intensity were reassigned as negative, revealing that some of the indeterminate samples may have resulted from non-specific reactivity or cross-reactivity with other antigens. Interestingly, samples with strong rgp21 I/II intensity displayed significantly higher S/CO or COI values than samples with faint intensity ([Supplementary Figure S1](#DS1){ref-type="supplementary-material"}). Taken together, the correlation between higher reactivity indexes and higher diagnostic reliability and the observation that the 2 LIA-indeterminate samples with strong rgp21 I/II intensity retested HTLV positive, support the view that LIA-indeterminate samples with strong intensities are more likely to still be in the seroconversion period, and should be paid serious attention.

Although the qPCR method used in our study did not detect all the specimens, our results indicated that qPCR was useful for resolving inconclusive confirmatory tests. Due to the large numbers of uncertain results and the high cost of WB and LIA assays, we propose employing qPCR first, followed by WB or LIA to test any qPCR-negatives. Other studies also recommend this strategy, which has been shown to reduce costs and improve the accuracy of HTLV-1/2 diagnosis ([@B7]; [@B8]).

Without a prophylactic vaccine and with limited available treatment options for HTLV-related diseases, recommendations for the deferral and reentry of blood donors are necessary, especially in China where HTLV-1/2 screening is underdeveloped. Based on our study, we suggest that donors with a final positive interpretation by a confirmatory test should be deferred permanently but donors returning a negative result should be reentered. Additionally, donors with indeterminate results should be followed-up, and recollected specimens should be confirmed through the same supplemental test.

Conclusion {#S5}
==========

In this study, we compared the performance of four commercially available kits for screening anti-HTLV-1/2 antibodies and used WB and LIA as confirmatory tests. We also proposed a new testing algorithm for screening and confirming HTLV-1/2 in a low prevalence region ([Figure 3](#F3){ref-type="fig"}). We recommend Roche-ECLIA as a second screening test in blood centers/banks to rule out large numbers of false-positives. Where local equipment is lacking, all RR specimens would need to be confirmed in reference labs. To minimize the risk of misdiagnosing true positives, samples that are reactive to Murex-ELISA or Roche-ECLIA should be further confirmed. Taking the cost into consideration, we suggest that these should be quantified using qPCR first, and then the negatives should be subjected to LIA but not WB to improve the diagnostic accuracy.

![Test algorithm for screening and confirmation of HTLV-1/2 infection in low-endemic areas. ELISA, enzyme-linked immunosorbent assays, CLIA, chemiluminescence immunoassays; ECLIA, electrochemiluminescence immunoassays. +: positive/reactive; −: negative/non-reactive.](fmicb-11-01151-g003){#F3}
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CLIA

:   chemiluminescence immunoassay

ECLIA

:   electrochemiluminescence immunoassay

ELISA

:   enzyme-linked immunosorbent assay

HTLV-1/2

:   human T-cell lymphotropic virus type ½

LIA

:   line immunoassay

NCCL

:   National Center for Clinical Laboratories

PPV

:   positive predictive value

RR

:   repeatedly reactive

WB

:   western blot.
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